uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Detection and quantification of auto-antibodies against proteins and peptides involved in Alzheimer’s disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2019 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Alzheimer’s disease (AD) is a neurodegenerative disease, which is estimated to affect about 80 million people worldwide by the year 2040. There have been reports of auto-antibodies against amyloid-beta (Aβ) and tau in serum of AD patients and controls. However, the studies have had various outcomes, and therefore further investigation to clarify if and how auto-antibodies are involved in AD needs to be done. In this study, we aimed to detect, quantify and distinguish possible differences in auto-antibody levels in serum of (n=38) AD patients and (n=34) healthy controls. Further, to evaluate the possible role of auto-antibodies in AD. Three target antigens involved in AD, amyloid-beta 42 (Aβ42), tau and beta- nerve growth factor (β-NGF) were chosen and samples were analysed using ELISA. Our group was able to detect and quantify auto-antibodies against Aβ42, tau and β-NGF. However, no differences in the levels of these was found between AD patients vs controls. Further, there were no differences between genders and age does not have an impact. Grouping by cerebrospinal fluid (CSF) Aβ42 showed that AD patients with moderate levels (based on predefined cut-offs) of CSF Aβ42 produced more β-NGF auto-antibodies than controls (high group), indicating that auto β-NGF antibodies may have an effect on the cholinergic system. Binding to β-NGF may inhibit neuronal stimulation, generating negative cascade effects. Similar results were found when categorisation by CSF tau and tau/Aβ42 was done. Identification of auto-antibodies against pathological and functional proteins may be proof of their importance in AD. The found differences between and within the cohorts confirms previous studies, but does not give clarity of how auto-antibodies are involved in AD. Nevertheless, the outcomes of our study should be taken with caution. Limitations, affecting the procedure, such as lack of time, lead to difficulties in terms of validation of the study. Overall, this demands further conformational research to be done in the future.  

Place, publisher, year, edition, pages
2019. , p. 38
Keywords [en]
Alzheimers disease, auto antibodies
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:uu:diva-406871OAI: oai:DiVA.org:uu-406871DiVA, id: diva2:1414675
External cooperation
Karolinska Institutet
Subject / course
Pharmaceutical Biosciences
Educational program
Master of Science Programme in Pharmacy
Supervisors
Examiners
Available from: 2020-03-16 Created: 2020-03-14 Last updated: 2020-03-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

By organisation
Department of Pharmaceutical Biosciences
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf